[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-456573-105":59,"doc-detail-456573-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","current-therapeutic-landscape-of-dry-eye-and-meibomian-gland-disease","Current therapeutic landscape of dry eye and meibomian gland disease","","Current therapeutic landscape of dry eye disease (DED) and meibomian gland dysfunction (MGD) is expanded through pharmacologic, biologic, and device-based approaches targeting core etiologies: aqueous deficiency and meibomian gland–related tear film instability. Emphasis extends to adjunctive domains including inflammation, microbial imbalance, and mucin deficiency. Reviews and studies summarize mechanism-driven mucin secretagogues and tear-film–oriented diagnosis, protocol-based intense pulsed light therapy, deep-learning imaging for microvasculature subtypes, antibiotic roles, and antioxidant anti-inflammatory modulation of ocular surface stress pathways.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/current-therapeutic-landscape-of-dry-eye-and-meibomian-gland-disease/456573/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/current-therapeutic-landscape-of-dry-eye-and-meibomian-gland-disease/456573.png","ImageObject",300,407,{"name":92,"@type":93},"LangkahRina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which primary etiologies does the issue focus on for dry eye disease and MGD therapy?","Question",{"text":112,"@type":113},"It focuses on aqueous deficiency and meibomian gland–related tear film instability, while also addressing inflammation, microbial imbalance, and mucin deficiency.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How are mucin secretagogues positioned in the therapeutic framework?",{"text":117,"@type":113},"They are described as mechanism-driven therapies that reinforce the tear film’s mucin layer and support tear stability and ocular surface repair, including evidence from randomized and real-world studies.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the editorial conclude about integrating modern treatments for ocular surface homeostasis?",{"text":121,"@type":113},"It highlights convergence of pharmacologic, biologic, and procedural innovations that aim to restore homeostasis rather than only relieve symptoms, using targeted, time-limited adjuncts when appropriate.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},456573,1791112609,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":14,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":24,"preview_page_count":4},962090893776,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","| Access this article online |\n| --- |\n| Quick Response Code: |\n| |\n| Website:\u003Cbr>[http://journals.lww.com/TJOP](http://journals.lww.com/TJOP) |\n| DOI:\u003Cbr>10.4103/tjo.TJO-D-25-00185 |\n\nSubmission: 06-11-2025  \nAccepted: 06-11-2025  \nPublished: 22-12-2025  \nEditorial  \nTaiwan J Ophthalmol 2025;15:503‑504  \nCurrent therapeutic landscape of dry eye and meibomian gland disease  \nThis issue of the Taiwan Journal of  \nOphthalmology brings together a diverse collection of studies that collectively expand the therapeutic landscape of dry eye disease (DED) and meibomian gland dysfunction (MGD) . The central focus lies on interventions that target the primary etiologies – aqueous deficiency and meibomian gland‑related tear film instability while also emphasizing the importance of adjunctive domains such as inflammation, microbial imbalance, and mucin deficiency. Taken together, these contributions highlight how modern ocular surface management increasingly integrates pharmacologic, biologic, and device‑based strategies to restore homeostasis rather than merely relieve symptoms.  \nSun et al. and Koh e t al. deepened understanding of mucin secretagogues as mechanism‑driven therapies for reinforcing the tear film’smucin layer. Sun et al. detailed the pathways – P2Y2 receptor activation, epidermal growth factor receptor (EGFR)– mitogen‑activated protein kinase (MAPK) signaling, and cytokine modulation (Interleukin [IL]‑13 and tumor necrosis factor‑alpha [TNF‑α ]) – that regulate secreted and membrane‑associated mucins, explaining how diquafosoland rebamipide enhance goblet‑cell secretion and epithelial repair. Koh etal. placed these agents within the tear film‑oriented Diagnosis framework, summarizing evidence from randomized and real‑world studies showing improved tear stability and ocular surface staining. Both reviews emphasized that these agents  \nThis is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercialNoDerivatives 4.0 License (CC BY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.  \nFor reprints [contact:](contact: WKHLRPMedknow_reprints@wolterskluwer.com)[ WKHLRPMedknow_reprints@wolterskluwer.com](contact: WKHLRPMedknow_reprints@wolterskluwer.com)  \nare now essential in Asian practice and represent a transition from supplementationto biologic restoration of mucin integrity.  \nExtending beyond pharmacologic treatment, Ahn et al. provided a procedural overview of Intense Pulsed Light (IPL) therapy for MGD, synthesizing evidence from over 100 clinical studies. Rather than focusing on molecular mechanisms, their review examined practical aspects of treatment delivery – including device parameters, pulse energies, treatment intervals, and the incorporation of adjunctive procedures such as gland expression and heated masks. By identifying common procedural patterns (typically three to four sessions at two‑to 3‑week intervals) and emphasizing consistency in technique, they proposed a structured approach for optimizing the outcomes and tailoring IPL regimens to individual patients. This work reframes IPL as a protocol‑dependent, procedure‑centered therapy.  \nLee et al. introduced a novel quantitative imaging approach for assessing the bulbar conjunctival microvasculature in patients with dry eye. Using a deep‑learning‑based optical system, they compared Sjögren’sand non‑Sjögren’s subtypes and found that vessel diameter was significantly greater in autoimmune‑associated dry eye, despite comparable symptoms and tear parameters. In non‑Sjögren’s cases, blood flow rate correlated with meibomian‑gland indices, highlighting an interplay between lipid‑layer dysfunction and conjunctival microcirculation. These results suggest that conjunctival microvascular morphology may serve as abiomarker for subtype differentiation and  \nHow to cite this article: Seo KY. C","cbCaicqLfXi8p9u2","https://ap.wps.com/l/cbCaicqLfXi8p9u2","pdf",283283,"English","# Editorial\n## Therapeutic targets in DED and MGD\n## Mucin secretagogues and tear-film restoration\n## Intense Pulsed Light (IPL) for MGD\n## Quantitative deep-learning imaging of microvasculature\n## Microbial imbalance and antibiotics\n## Inflammation, oxidative stress, and antioxidant strategies","[{\"question\":\"Which primary etiologies does the issue focus on for dry eye disease and MGD therapy?\",\"answer\":\"It focuses on aqueous deficiency and meibomian gland–related tear film instability, while also addressing inflammation, microbial imbalance, and mucin deficiency.\"},{\"question\":\"How are mucin secretagogues positioned in the therapeutic framework?\",\"answer\":\"They are described as mechanism-driven therapies that reinforce the tear film’s mucin layer and support tear stability and ocular surface repair, including evidence from randomized and real-world studies.\"},{\"question\":\"What does the editorial conclude about integrating modern treatments for ocular surface homeostasis?\",\"answer\":\"It highlights convergence of pharmacologic, biologic, and procedural innovations that aim to restore homeostasis rather than only relieve symptoms, using targeted, time-limited adjuncts when appropriate.\"}]","Current therapeutic landscape of dry eye and meibomian gland disease | PDF",1790746414]